Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relapsed/Refractory ETP‐ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant

1 Jun 2020

Abstract excerpt

T-lymphoblastic leukemia/ lymphoma (T-ALL/LBL) is a malignant neoplasm of immature T-cells with characteristic immunophenotypic subtypes that correspond to T-cell maturation stages. Early T-cell precursor lymphoblastic leukemia (ETP-ALL) is one such subtype, which is derived from thymic cells at the early T-cell precursor differentiation stage and make up 5% to 16% of T-ALL cases.1 ETP-ALL cells are derived from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Childhood Cancer Survivors' Quality of Life
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32647798
DOI: 10.1097/hs9.0000000000000379

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relapsed/Refractory ETP‐ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell TransplantPMID 32647798Read ↗

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclaxSemantic proximity Read ↗

How I treat ETP-ALL in childrenSemantic proximity Read ↗

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterationsSemantic proximity Read ↗

Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine SignalingSemantic proximity Read ↗

Short Course Venetoclax with standard chemotherapy is effective in Early T cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.Semantic proximity Read ↗

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read ↗

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.Semantic proximity Read ↗

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesSemantic proximity Read ↗

Efficacy and Safety of the Third‐Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Successful treatment of a B/T MPAL patient by chemo-free treatment with Venetoclax,Azacitidine and BlinatumomabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.